HSA grants interim authorisation for use of Pfizer Comirnaty bivalent vaccine in Singapore

HSA has granted interim authorisation for the Pfizer Comirnaty bivalent vaccine.

The vaccine will target both the original Sars-CoV-2 coronavirus and the Omicron BA.4 and BA.5 subvariants.

It is authorised for use as a booster vaccine for those aged 12 and above who have received their primary series vaccination.